Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting
Vakaramoko Diaby,
Ching-Yu Wang,
Hussain Alqhtani,
Sascha van Boemmel-Wegmann,
Askal Ayalew Ali,
Rajesh Balkrishnan,
Yu Ko,
Sofia Palacio,
Gilberto de Lima Lopes
Affiliations
Vakaramoko Diaby
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA; Corresponding author.
Ching-Yu Wang
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA
Hussain Alqhtani
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA; Department of Clinical Pharmacy, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia
Sascha van Boemmel-Wegmann
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA
Askal Ayalew Ali
Economic, Social & Administrative Pharmacy, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida, USA
Rajesh Balkrishnan
Population Health and Prevention Research, University of Virginia School of Medicine, Charlottesville, Virginia, USA
Yu Ko
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
Sofia Palacio
Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, Florida, USA
Gilberto de Lima Lopes
Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, Florida, USA
The present data article aims to describe the input parameters for a Markov model assessing the cost-effectiveness of four treatment sequences for patients with HER-2 positive metastatic breast cancer. The model input parameters include costs for physician visits, drugs, adverse event management, computed tomography (CT) scan, laboratory tests, echocardiogram, utilities, disutilities as well as the shape and scale parameters of a log-logistic distribution used for the transition probabilities. Keywords: Markov model, Metastatic breast cancer, Cost-effectiveness analysis, Treatment sequence
